HyperRHO® S/D Mini-Dose (RhO[D] immune globulin [human]) is recommended to prevent the isoimmunization of RhO(D)-negative women at the time of spontaneous or induced abortion of up to 12 weeks' gestation provided the following criteria are met: The mother must be RhO(D) negative and must not already be sensitized to the RhO(D) antigen. The father is not known to be RhO(D) negative. Gestation is not more than 12 weeks at termination.

HyperRHO S/D is an immune globulin with a high level of preformed antibodies against rhesus (Rh)-positive blood cells.
The injection of an RHO(D) immune globulin provides a passive immunity for rapid immune protection and an acute response in high-risk situations.
HyperRHO S/D destroys any Rh-positive blood cells that may have entered the mother's bloodstream and prevents the mother's immune system from producing Rh-positive antibodies, thus protecting the baby from developing hemolytic disease.

Each single-dose syringe of HyperRHO S/D contains sufficient anti-RhO(D) to effectively suppress the immunizing potential of 15 mL of Rh-positive red blood cells.

Antepartum and postpartum administration of a single dose of HyperRHO S/D to susceptible Rh-negative women reduces the incidence of Rh isoimmunization to less than 0.1%.

Effective Protection
HyperRHO S/D destroys Rh-positive cells in the mother's body, prevents the mother's immune system from producing Rh-positive antibodies, and protects the baby from contracting HDN.